tions. Some of these dilemmas verge on the philosophicalabsence of evidence does not necessarily imply evidence of absence. But other problems are more practical, as publishing negative data is not simply a matter of stating that a given clinical trial has failed before we nod and move on to the next trial. For this information to be useful, it must be vetted with the same rigor as positive results, lest we allow inaccurate negative findings to influence clinical practice. This includes passage through the filter of the peer-review process to make sure that the experimental design and statistical analysis are sound and that any revisions that might be necessary to make it hold water properly are undertaken. As any scientist or referee knows, this process can be protracted, and there does not seem to be much incentive to producing an article that proves that the outcome one was hoping to find is not there.
At the same time, it would be disingenuous of journals-particularly high profile ones-to say that they would be equally willing to publish negative and positive data from clinical trials. In other words, the inclusion of every trial in a registry as a prerequisite for publication does not imply that the results of peerreviewed research will be equally visible. Instead, it seems more likely that trials reporting positive results will continue to appear predominantly in high-profile publications, whereas those showing negative data might fill the pages of more modest titles, with a relatively limited influence on the decision-making process of practicing clinicians.
Although pharmaceutical companies are the targets of most criticism regarding the unwillingness to publish negative results, scientists and clinicians would be the ones investing a significant fraction of their human capital to make these data available. It is therefore questionable whether there exists enough incentive for researchers to publish negative results. Funding bodies-public or private-should begin to look more favorably on scientists who make the effort to publish negative data.
Creating a database with data from every clinical trial might benefit patients, clinicians and researchers. But its implementation and subsequent curation need to be carefully planned and will require the commitment of researchers, clinicians, scientific journals, pharmaceutical companies, funding agencies and regulatory authorities. In an era in which we are already experiencing an overload of scientific data, an unstructured deluge of information that few of us have time to process should be avoided.
The sounds of silence
